Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 9/2008

01-09-2008 | Original Paper

Fibrosis, Portal Hypertension, and Hepatic Volume Changes Induced by Intra-arterial Radiotherapy with 90Yttrium Microspheres

Authors: T. F. Jakobs, S. Saleem, B. Atassi, E. Reda, R. J. Lewandowski, V. Yaghmai, F. Miller, R. K. Ryu, S. Ibrahim, K. T. Sato, L. M. Kulik, M. F. Mulcahy, R. Omary, R. Murthy, M. F. Reiser, R. Salem

Published in: Digestive Diseases and Sciences | Issue 9/2008

Login to get access

Abstract

Purpose To identify changes in hepatic parenchymal volume, fibrosis, and induction of portal hypertension following radioembolization with glass microspheres for patients with metastatic disease to the liver. Results In our series of sequential bilobar (n = 17) treatments, a mean decrease in liver volume of 11.8% was noted. In this group, a mean splenic volume increase of 27.9% and portal vein diameter increase of 4.8% were noted. For patients receiving unilobar treatments (n = 15), mean ipsilateral lobar volume decrease of 8.9%, contralateral lobar hypertrophy of 21.2%, and a 5.4% increase in portal vein diameter were also noted. These findings were not associated with clinical toxicities. Conclusion90Yttrium radioembolization utilizing glass microspheres in patients with liver metastases results in changes of hepatic parenchymal volume and also induced findings suggestive of fibrosis and portal hypertension. Further studies assessing the long-term effects are warranted.
Literature
1.
2.
de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18(16):2938–2947PubMed
3.
Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P et al (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355(9209):1041–1047PubMedCrossRef
4.
Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22(2):229–237PubMedCrossRef
5.
Giantonio BJ, Catalano PJ, Meropol NJ, O’Dwyer PJ, Mitchell EP, Alberts SR et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the eastern cooperative oncology group study E3200. J Clin Oncol 25(12):1539–1544
6.
Emmanouilides C, Sfakiotaki G, Androulakis N, Kalbakis K, Christophylakis C, Kalykaki A et al (2007) Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. BMC Cancer 7:91PubMedCrossRef
7.
Dawson LA, McGinn CJ, Normolle D, Ten Haken RK, Walker S, Ensminger W et al (2000) Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol 18(11):2210–2218PubMed
8.
Kennedy AS, Nutting C, Coldwell D, Gaiser J, Drachenberg C (2004) Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys 60(5):1552–1563PubMed
9.
Jakobs TF, Hoffmann RT, Poepperl G, Schmitz A, Lutz J, Koch W et al (2007) Mid-term results in otherwise treatment refractory primary or secondary liver confined tumours treated with selective internal radiation therapy (SIRT) using (90)Yttrium resin-microspheres. Eur Radiol 17(5):1320–1330PubMedCrossRef
10.
Kennedy AS, Coldwell D, Nutting C, Murthy R, Wertman DE Jr, Loehr SP et al (2006) Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys 65(2):412–425PubMed
11.
Lewandowski RJ, Thurston KG, Goin JE, Wong CY, Gates VL, Van Buskirk M et al (2005) 90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135–150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging. J Vasc Interv Radiol 16(12):1641–1651PubMed
12.
Liu LX, Zhang WH, Jiang HC (2003) Current treatment for liver metastases from colorectal cancer. World J Gastroenterol 9(2):193–200PubMed
13.
Sharma RA, Van Hazel GA, Morgan B, Berry DP, Blanshard K, Price D et al (2007) Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 25(9):1099–1106
14.
Van Hazel G, Blackwell A, Anderson J, Price D, Moroz P, Bower G et al (2004) Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 88(2):78–85PubMedCrossRef
15.
Coldwell DM, Kennedy AS, Nutting CW (2007) Use of yttrium-90 microspheres in the treatment of unresectable hepatic metastases from breast cancer. Int J Radiat Oncol Biol Phys 69(3):800–804PubMed
16.
Moroz P, Anderson JE, Van Hazel G, Gray BN (2001) Effect of selective internal radiation therapy and hepatic arterial chemotherapy on normal liver volume and spleen volume. J Surg Oncol 78(4):248–252PubMedCrossRef
17.
Stubbs RS (2006) Portal hypertension and liver surgery following selective internal radiation therapy with 90Yttrium microspheres. J Clin Oncol 24(9):e15
18.
Kennedy A, Nag S, Salem R, Murthy R, McEwan AJ, Nutting C et al (2007) Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 68(1):13–23PubMed
19.
Liu DM, Salem R, Bui JT, Courtney A, Barakat O, Sergie Z et al (2005) Angiographic considerations in patients undergoing liver-directed therapy. J Vasc Interv Radiol 16(7):911–935PubMed
20.
Salem R, Thurston KG (2006) Radioembolization with 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 2: special topics. J Vasc Interv Radiol 17(9):1425–1439PubMed
21.
Salem R, Thurston KG (2006) Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. J Vasc Interv Radiol 17(8):1251–1278PubMedCrossRef
22.
Dancey JE, Shepherd FA, Paul K, Sniderman KW, Houle S, Gabrys J et al (2000) Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med 41(10):1673–1681PubMed
23.
Salem R, Thurston KG, Carr BI, Goin JE, Geschwind JF (2002) Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. J Vasc Interv Radiol 13(9 Pt 2):223–229CrossRef
24.
Goin JE, Salem R, Carr BI, Dancey JE, Soulen MC, Geschwind JF et al (2005) Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. J Vasc Interv Radiol 16(2 Pt 1):205–213PubMed
25.
Ho S, Lau WY, Leung TW, Chan M, Johnson PJ, Li AK (1997) Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med 24(3):293–298PubMed
26.
Ho S, Lau WY, Leung TW, Chan M, Ngar YK, Johnson PJ et al (1996) Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours. Eur J Nucl Med 23(8):947–952PubMedCrossRef
27.
Lewandowski RJ, Sato KT, Atassi B, Ryu RK, Nemcek AA, Jr, Kulik L et al (2007) Radioembolization with (90)y microspheres: angiographic and technical considerations. Cardiovasc Intervent Radiol 30(4):571–592PubMedCrossRef
28.
Barnard JA, Marshall GS, Neblett WW, Gray G, Ghishan FK (1986) Noncirrhotic portal fibrosis after Wilms’ tumor therapy. Gastroenterology 90(4):1054–1056PubMed
29.
Phillips R, Karnofsky DA, Hamilton LD, Nickson JJ (1954) Roentgen therapy of hepatic metastases. Am J Roentgenol Radium Ther Nucl Med 71(5):826–834PubMed
30.
Wharton JT, Delclos L, Gallager S, Smith JP (1973) Radiation hepatitis induced by abdominal irradiation with the cobalt 60 moving strip technique. Am J Roentgenol Radium Ther Nucl Med 117(1):73–80PubMed
31.
Clement B, Grimaud JA, Campion JP, Deugnier Y, Guillouzo A (1986) Cell types involved in collagen and fibronectin production in normal and fibrotic human liver. Hepatology 6(2):225–234PubMedCrossRef
32.
Yokoi Y, Namihisa T, Matsuzaki K, Miyazaki A, Yamaguchi Y (1988) Distribution of Ito cells in experimental hepatic fibrosis. Liver 8(1):48–52PubMed
33.
Ingold JA, Reed GB, Kaplan HS, Bagshaw MA (1965) Radiation Hepatitis. Am J Roentgenol Radium Ther Nucl Med 93:200–208PubMed
34.
Alati T, Van Cleeff M, Strom SC, Jirtle RL (1988) Radiation sensitivity of adult human parenchymal hepatocytes. Radiat Res 115(1):152–160PubMedCrossRef
35.
Sempoux C, Horsmans Y, Geubel A, Fraikin J, Van Beers BE, Gigot JF et al (1997) Severe radiation-induced liver disease following localized radiation therapy for biliopancreatic carcinoma: activation of hepatic stellate cells as an early event. Hepatology 26(1):128–134PubMedCrossRef
36.
Lewin K, Millis RR (1973) Human radiation hepatitis. A morphologic study with emphasis on the late changes. Arch Pathol 96(1):21–26PubMed
37.
Fajardo LF, Colby TV (1980) Pathogenesis of veno-occlusive liver disease after radiation. Arch Pathol Lab Med 104(11):584–588PubMed
38.
Fajardo LF (2005) The pathology of ionizing radiation as defined by morphologic patterns. Acta Oncol 44(1):13–22PubMedCrossRef
39.
Lim L, Gibbs P, Yip D, Shapiro JD, Dowling R, Smith D et al (2005) Prospective study of treatment with selective internal radiation therapy spheres in patients with unresectable primary or secondary hepatic malignancies. Intern Med J 35(4):222–227PubMedCrossRef
40.
Stubbs RS, O’Brien I, Correia MM (2006) Selective internal radiation therapy with 90Y microspheres for colorectal liver metastases: single-centre experience with 100 patients. ANZ J Surg 76(8):696–703PubMedCrossRef
41.
Wong CY, Salem R, Raman S, Gates VL, Dworkin HJ (2002) Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI. Eur J Nucl Med Mol Imaging 29(6):815–820PubMedCrossRef
42.
Wong CY, Salem R, Qing F, Wong KT, Barker D, Gates V et al (2004) Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases: comparison of quantitative and visual analyses by 18F-FDG PET. J Nucl Med 45(11):1892–1897PubMed
43.
Wong CY, Qing F, Savin M, Campbell J, Gates VL, Sherpa KM et al (2005) Reduction of metastatic load to liver after intraarterial hepatic yttrium-90 radioembolization as evaluated by [18F]fluorodeoxyglucose positron emission tomographic imaging. J Vasc Interv Radiol 16(8):1101–1106PubMed
44.
Wong CY, Savin M, Sherpa KM, Qing F, Campbell J, Gates VL et al (2006) Regional yttrium-90 microsphere treatment of surgically unresectable and chemotherapy-refractory metastatic liver carcinoma. Cancer Biother Radiopharm 21(4):305–313PubMedCrossRef
45.
DeLeve LD, Shulman HM, McDonald GB (2002) Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 22(1):27–42PubMedCrossRef
46.
Dulley FL, Kanfer EJ, Appelbaum FR, Amos D, Hill RS, Buckner CD et al (1987) Venocclusive disease of the liver after chemoradiotherapy and autologous bone marrow transplantation. Transplantation 43(6):870–873PubMed
47.
DeLeve LD, Kaplowitz N (1995) Mechanisms of drug-induced liver disease. Gastroenterol Clin North Am 24(4):787–810PubMed
48.
Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M et al (2004) Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15(3):460–466PubMedCrossRef
49.
Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM (2005) Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 200(6):845–853PubMedCrossRef
50.
Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM et al (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24(13):2065–2072PubMedCrossRef
51.
Pawlik TM, Olino K, Gleisner AL, Torbenson M, Schulick R, Choti MA (2007) Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg 11(7):860–868PubMedCrossRef
Metadata
Title
Fibrosis, Portal Hypertension, and Hepatic Volume Changes Induced by Intra-arterial Radiotherapy with 90Yttrium Microspheres
Authors
T. F. Jakobs
S. Saleem
B. Atassi
E. Reda
R. J. Lewandowski
V. Yaghmai
F. Miller
R. K. Ryu
S. Ibrahim
K. T. Sato
L. M. Kulik
M. F. Mulcahy
R. Omary
R. Murthy
M. F. Reiser
R. Salem
Publication date
01-09-2008
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 9/2008
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-007-0148-z

Other articles of this Issue 9/2008

Digestive Diseases and Sciences 9/2008 Go to the issue

Introduction

Body Mass Index and Gastroesophageal Reflux Disease: Implications of the Obesity Epidemic

Original Paper

Scoring System for Predicting Response to Chemoradiotherapy, Including 5-Fluorouracil and Platinum, for Patients with Esophageal Cancer

Review

Body Mass Index and the Efficacy of Acid-Mediating Agents for GERD

Original Paper

Adherence, Internalization, and Persistence of Helicobacter pylori in Hepatocytes

Original Paper

A Meta-Analysis on the Efficacy of Probiotics for Maintenance of Remission and Prevention of Clinical and Endoscopic Relapse in Crohn’s Disease

Letter to the Editor

Des-Acylated Ghrelin, Rather Than Acylated Ghrelin, Might Be More Valuable in Inflammatory Bowel Diseases
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits